Please sign in to follow a disease.
Connective tissue disorder
MONDO:0003900A disease involving the connective tissue.
Also known as: connective tissue disease, connective tissue disease or disorder, connective tissue diseases, connective tissue disorder, connective tissue disorders, disease of connective tissue, disease or disorder of connective tissue, disease, connective tissue
4076 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Rollover study offers continued itacitinib access for chronic disease patients
Disease control TerminatedThis study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental combo for tough leukemia hits early snag
Disease control TerminatedThis early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the d…
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a common blood pressure drug shrink kidney tumors?
Disease control TerminatedThis pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasiv…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ankle implant tracked for Long-Term success in arthritis patients
Disease control TerminatedThis study followed 65 adults with ankle arthritis (from wear-and-tear, injury, or conditions like rheumatoid arthritis) who received the Cadence Total Ankle System implant. Researchers tracked how long the implant lasted without needing removal or revision, checking at 2, 5, and…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New RA drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who had not improved enough on other treatments. The goal was to see if the drug could reduce joint swelling and pain. However, the trial was terminated early, so the…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy takes on stubborn autoimmune diseases
Disease control TerminatedThis early study tested a new cell therapy called LUCAR-G79 in just 3 adults with severe autoimmune diseases that did not respond to standard treatments. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. The main goals…
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental AML drug trial halted early after only 8 patients
Disease control TerminatedThis early-stage trial tested a new drug called tomivosertib in 8 adults with acute myeloid leukemia (AML) that had come back or not responded to prior treatments. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control TerminatedThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Shoulder implant under review: will it last 10 years?
Disease control TerminatedThis study looked at a shoulder implant used to treat pain and joint problems from conditions like arthritis, fractures, and rotator cuff tears. It involved 67 adults who received the implant and tracked how long it lasted and any side effects over 10 years. The goal was to confi…
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for myelofibrosis patients who failed standard therapy?
Disease control TerminatedThis study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental combo for resistant leukemia shows early promise but trial halted
Disease control TerminatedThis pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The …
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cancer drug BBI-355 trial halted early – what we know
Disease control TerminatedThis early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…
Phase: PHASE1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental immune cell therapy targets tough leukemia
Disease control TerminatedThis early-phase study tested an off-the-shelf natural killer (NK) cell therapy called SAR445419 in adults with acute myeloid leukemia that returned or didn't respond to treatment. Participants received chemotherapy followed by the NK cells to see if it was safe and could help co…
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Cancer drug cocktail shows promise for tough blood cancers, but study halted early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Promising combo for AML after transplant falls short as trial ends early
Disease control TerminatedThis study tested whether adding venetoclax and azacitidine after a stem cell transplant could help people with acute myeloid leukemia (AML) live longer. It included adults and teens who had recently received a transplant. The trial was stopped early, so the full benefits and ris…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Focused ultrasound trial for rare sarcoma halted early
Disease control TerminatedThis study tested whether focused ultrasound could partially destroy a rare soft-tissue cancer called undifferentiated pleomorphic sarcoma and boost the body's immune response. Only 5 people were enrolled before the trial was terminated. The main goal was to check safety and see …
Phase: NA • Sponsor: Matthew Bucknor • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control TerminatedThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
CML drug combo aims for Treatment-Free remission, but trial stalls
Disease control TerminatedThis phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small…
Phase: PHASE3 • Sponsor: Sarit Assouline • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control TerminatedThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Mini transplant shows promise for blood cancers – but trial ended early
Disease control TerminatedThis study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Rheumatoid arthritis drug study halted early – what we know
Disease control TerminatedThis study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental antibody drug tested for stubborn blood cancers, but study halted early
Disease control TerminatedThis study tested a drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not respond to or came back after standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells.…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New antibody drug tested for tough blood cancers – but trial stopped early
Disease control TerminatedThis study tested a new experimental drug called GEN3014 (HexaBody-CD38) in people with multiple myeloma and other blood cancers that had returned or become resistant to treatment. The main goal was to check safety and find the right dose. The trial was terminated early, so the f…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Cord blood transplant trial for blood cancers halted early
Disease control TerminatedThis study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Discoid lupus drug trial halted midway
Disease control TerminatedThis study tested an experimental drug called daxdilimab in 72 adults with moderate-to-severe discoid lupus erythematosus, a skin condition that causes scarring and hair loss. The goal was to see if the drug could reduce disease activity compared to a placebo. However, the trial …
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for tough leukemias? trial of vodobatinib begins, then stops
Disease control TerminatedThis study tested a new drug called Vodobatinib (K0706) in people with chronic myeloid leukemia or a related leukemia who had not responded to at least three other treatments. The trial was split into parts: first in healthy volunteers to check safety, then in patients to find th…
Phase: PHASE1, PHASE2 • Sponsor: Sun Pharma Advanced Research Company Limited • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Blood cancer transplant study tests safer GVHD prevention
Disease control TerminatedThis phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental combo for tough leukemia shows promise in early trial
Disease control TerminatedThis pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug tested for Post-Transplant blood cancers — but study halted early
Disease control TerminatedThis pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…
Phase: PHASE2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control TerminatedThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple-Drug attack on tough leukemia shows promise but trial halted
Disease control TerminatedThis early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into r…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental drug tested for rare cancer, trial stopped early
Disease control TerminatedThis study tested a drug called XmAb23104 in people with advanced sarcoma, a rare cancer. The goal was to see if the drug could shrink tumors and if it was safe. Only 6 people took part before the study was ended early.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Promising prostate cancer combo trial stalls after just 7 patients
Disease control TerminatedThis phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control TerminatedThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase: PHASE2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Experimental drug gentulizumab tested for tough blood cancers – but trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Lupus flare prevention drug trial halted early
Disease control TerminatedThis study tested a drug called PRV-3279 to see if it could prevent lupus flares in people with active systemic lupus erythematosus (SLE). The trial included 28 adults with moderate to severe lupus who had improved after steroid treatment. The study was terminated early, so resul…
Phase: PHASE2 • Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Stem cell transplant study halted early: which prep works best?
Disease control TerminatedThis study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…
Phase: PHASE3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental chemo cocktail targets resistant leukemia
Disease control TerminatedThis study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for hard-to-treat blood cancers? early trial stopped short
Disease control TerminatedThis study tested a new drug called S227928, alone or with another drug (venetoclax), in people with certain blood cancers (AML, MDS/AML, or CMML) that returned or didn't respond to prior therapy. The goal was to find a safe dose and see if it helps. The trial was terminated earl…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising drug for rare skin ulcers shows early potential
Disease control TerminatedThis study tested a drug called spesolimab in 5 adults with moderate to severe pyoderma gangrenosum, a rare autoimmune disease that causes painful skin ulcers. The goal was to see if the drug could help heal the ulcers and to understand how the body's immune system responds. The …
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental cell therapy for tough leukemia shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new cell therapy called GDX012 in 16 people with acute myeloid leukemia (AML) that had come back or not responded to standard treatment. The main goals were to check safety, find the best dose, and see if the therapy could control the cancer. The s…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
CBD-Hydroxychloroquine combo tested for arthritis pain – but trial ends early
Disease control TerminatedThis study tested a combination pill called IHL-675A, which contains cannabidiol (CBD) and hydroxychloroquine, in people with rheumatoid arthritis. The goal was to see if it safely reduces pain and improves daily function. The trial planned to enroll 128 volunteers but was termin…
Phase: PHASE2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Experimental drug HZN-825 tested for rare scleroderma lung and skin damage
Disease control TerminatedThis trial tested an experimental drug called HZN-825 in about 300 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can damage the lungs. Participants took either a low dose, a high dose, or a placebo daily for 52 weeks. …
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immune cell therapy tested for tough childhood cancers
Disease control TerminatedThis early-phase study tested a treatment using donated natural killer (NK) cells from cord blood, combined with chemotherapy, for children and young adults with solid tumors that returned or didn't respond to standard care. The goal was to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug for tough leukemias hits dead end
Disease control TerminatedThis early-phase trial tested an oral drug called NMS-03592088 in 63 adults with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) that had come back or not responded to standard treatments. The goal was to check safety, find the right dose, and see if it cou…
Phase: PHASE1, PHASE2 • Sponsor: Nerviano Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental drug voruciclib tested in desperate blood cancer patients
Disease control TerminatedThis early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…
Phase: PHASE1 • Sponsor: MEI Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental combo for MDS and AML shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was…
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Cord blood immune cells tested against tough leukemia
Disease control TerminatedThis early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…
Phase: PHASE1, PHASE2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lupus skin drug trial halted early – only 8 volunteers joined
Disease control TerminatedThis study tested an experimental drug called PF-06823859 for adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The trial was stopped early and only enrolled 8 people instead of the planned 48, so results…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New shoulder implant tested for severe arthritis – but study halted early
Disease control TerminatedThis study looked at the TITAN Reverse Shoulder System, a device used to replace the shoulder joint in people with severe arthritis and a torn rotator cuff. The goal was to see if it relieves pain and improves movement. About 151 people were planned to take part, but the study wa…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo for tough leukemias hits snag: trial ends early
Disease control TerminatedThis phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo aims to wipe out hidden leukemia cells
Disease control TerminatedThis phase II trial tested adding asciminib (ABL001) to standard tyrosine kinase inhibitor therapy in 7 people with chronic myeloid leukemia who still had traces of cancer. The goal was to see if the combination could eliminate remaining cancer cells. The study was terminated ear…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo tried for tough blood cancers
Disease control TerminatedThis early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New Triple-Drug approach targets leukemia in vulnerable patients
Disease control TerminatedThis early-phase study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The study was stopped early, so resul…
Phase: PHASE1 • Sponsor: Brian Jonas • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Gel that promises faster healing after tooth extraction falls short in early trial
Disease control TerminatedThis study tested a gel made from hyaluronic acid and amino acids (Gumblast) to see if it helps surgical wounds in the mouth heal better. It involved 28 adults who needed at least two teeth extracted, with one socket treated with the gel and the other left to heal normally. The t…
Phase: NA • Sponsor: The Wave Innovation Group s.r.l. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Lupus skin drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising combo for tough blood cancer hits snag, study stopped early
Disease control TerminatedThis study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell therapy targets stubborn leukemia in early trial
Disease control TerminatedThis early-phase study tested a new treatment called LCAR-AMDR cells in 4 people with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment uses specially engineered immune cells to target two proteins (CLL1 and CD33) on leukemia cells. The…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug vixarelimab tested for two scarring lung diseases
Disease control TerminatedThis study tested the drug vixarelimab against a placebo in people with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-associated interstitial lung disease (SSc-ILD). The goal was to see if it could preserve lung function over 52 weeks. The trial was terminated early, …
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental drug shows promise for Hard-to-Treat prostate cancer
Disease control TerminatedThis phase 2 study tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The goal was to see if the drug could slow the cancer and to study bone and blood markers. The trial was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental combo for tough leukemias shows early promise
Disease control TerminatedThis early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Rheumatoid arthritis combo drug trial stalls after just 2 patients
Disease control TerminatedThis early-stage trial tested whether adding an experimental drug called VIB4920 to standard TNF-inhibitor therapy could improve disease control in people with rheumatoid arthritis. Only 2 participants were enrolled before the study was terminated, so no meaningful conclusions ca…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New antibody drug takes on tough blood cancers
Disease control TerminatedThis early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve …
Phase: PHASE1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental CAR t therapy targets lupus and related diseases – but trial ends early
Disease control TerminatedThis early-phase trial tested a single infusion of IMPT-514, a personalized CAR T cell therapy, in 3 adults with severe lupus, vasculitis, or inflammatory myopathy that did not respond to standard treatments. The goal was to check safety and see if the therapy could reset the imm…
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental IDH drug trial halted early – what we know so far
Disease control TerminatedThis early-stage study tested an experimental drug called HMPL-306 in 46 adults with advanced blood cancers (like leukemia) that have a specific genetic change called an IDH mutation. The goal was to find a safe dose and check for side effects. The study was stopped early, so res…
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Early-Stage lung blood pressure drug trial halted
Disease control TerminatedThis study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …
Phase: PHASE2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug DFP-10917 tested in Late-Stage trial
Disease control TerminatedThis study tested a new drug called DFP-10917 in adults with acute myeloid leukemia (AML) that had returned or not responded after 2 to 4 prior treatments. Participants received either DFP-10917 or one of several standard chemotherapy combinations. The goal was to see if DFP-1091…
Phase: PHASE3 • Sponsor: Delta-Fly Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take aim at stubborn leukemia
Disease control TerminatedThis early-stage trial tested a new therapy for patients with acute myeloid leukemia (AML) that had returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack cancer cells carrying a specific marker (CD123).…
Phase: PHASE1 • Sponsor: AvenCell Europe GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for leukemia patients too sick for chemo?
Disease control TerminatedThis phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve r…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental combo for rare blood cancers hits roadblock
Disease control TerminatedThis study tested whether adding sabatolimab to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2). The trial aimed to see if the combination improved survival. However, the study was stopped early, so we …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Lupus drug trial halted early: what we know
Disease control TerminatedThis study tested a weekly injection called telitacicept against a placebo in 91 people with moderate-to-severe lupus. The goal was to see if the drug could reduce disease activity and allow lower steroid doses. However, the trial was terminated early, so we have less information…
Phase: PHASE3 • Sponsor: Vor Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Promising combo for relapsed AML stalls as trial ends early
Disease control TerminatedThis phase 2 trial tested a combination of three oral drugs—decitabine, cedazuridine, and venetoclax—in adults whose acute myeloid leukemia (AML) came back after a donor stem cell transplant. The goal was to see if the drugs could kill cancer cells and achieve a complete remissio…
Phase: PHASE2 • Sponsor: Sanjay Mohan • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental AML drug minnelide tested in early trial
Disease control TerminatedThis early-phase study tested the safety and best dose of a drug called Minnelide in 27 adults with acute myeloid leukemia (AML) that had returned or not responded to prior therapy. The goal was to find the highest safe dose and check for side effects. The study was terminated ea…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo for rare bone marrow cancer shows early promise, but trial halted
Disease control TerminatedThis study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Promising combo for relapsed leukemia in kids hits early hurdle
Disease control TerminatedThis study tested a drug called gilteritinib, which targets a specific genetic change in leukemia cells, combined with standard chemotherapy in children and young adults (ages 6 months to 21 years) whose acute myeloid leukemia (AML) had returned or not responded to treatment. The…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental drug HZN-825 tested for rare autoimmune lung complication
Disease control TerminatedThis trial tested the drug HZN-825 in 174 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that can scar the lungs. Participants took the drug twice daily for 52 weeks to see if it helped maintain lung function and to check for side effects. The study w…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental AML combo trial halted early – what happened?
Disease control TerminatedThis early-phase trial tested an experimental drug called CWP232291 combined with the standard chemotherapy cytarabine in 15 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for signs of…
Phase: PHASE1, PHASE2 • Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Experimental blood cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Experimental combo targets Hard-to-Treat bone cancer
Disease control TerminatedThis early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to sta…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug shows promise for aggressive leukemia but carries serious clot risk
Disease control TerminatedThis study tested the drug ponatinib in 51 adults with a fast-growing form of chronic myeloid leukemia (CML) who had little or no prior treatment. The goal was to see if ponatinib could control the disease by blocking a protein that drives leukemia growth. However, the drug can c…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Lupus kidney drug trial halted midway
Disease control TerminatedThis study tested a drug called zetomipzomib for people with active lupus nephritis, a kidney disease caused by lupus. The goal was to see if the drug could improve kidney function better than a placebo over 52 weeks. The trial was terminated early, so results are limited. Partic…
Phase: PHASE2 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo aims to stop leukemia return in High-Risk patients
Disease control TerminatedThis study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in co…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Blood cancer drug fails to show promise in Post-Transplant trial
Disease control TerminatedThis early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose a…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug peresolimab tested for rheumatoid arthritis – study ends early
Disease control TerminatedThis study tested peresolimab, an experimental drug, in 491 adults with moderately-to-severely active rheumatoid arthritis who had not responded well to other treatments. The goal was to see if peresolimab could reduce joint pain and swelling better than a placebo. However, the s…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Sarcoidosis drug study halted after just 3 patients
Disease control TerminatedThis study tested whether the drug maraviroc could reduce inflammation in the lungs of people with active sarcoidosis. Participants took the drug for 6 weeks and had two lung exams (bronchoscopy) to measure immune cells before and after treatment. Only 3 people enrolled, and the …
Phase: NA • Sponsor: Kevin F. Gibson • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill combo aims to fight tough bone marrow cancer
Disease control TerminatedThis study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Promising cream for rare skin condition falls short in early trial
Disease control TerminatedThis study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial angiofibromas in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the size and redness of these skin growths. The trial was termi…
Phase: PHASE2 • Sponsor: Aucta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug BR108 tested in blood cancer patients – early results uncertain
Disease control TerminatedThis early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Smart device helps arthritis patients stay on track
Disease control TerminatedThis study looked at whether a smart injection device (Smartclic) helps rheumatoid arthritis patients take their etanercept medication as prescribed. Researchers tracked 60 patients in Colombia for 40 weeks, measuring how often they used the device and how their symptoms changed.…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Promising liposarcoma drug trial halted early
Disease control TerminatedThis study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow down cancer growth compared to a placebo. The trial was stopped early …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental cancer combo shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full resu…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental combo for tough blood cancers hits early hurdle
Disease control TerminatedThis early-stage trial tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine and venetoclax) in 25 people with relapsed or hard-to-treat acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. The study aimed to check…
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New transplant method shows promise for tough blood cancers
Disease control TerminatedThis study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo for tough blood cancers halted early — only 4 patients enrolled
Disease control TerminatedThis study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo for tough leukemia hits roadblock: trial stopped early
Disease control TerminatedThis early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising drug trial for painful skin ulcers halted early
Disease control TerminatedThis study tested a drug called vilobelimab for people with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The trial aimed to see if the drug could completely close the ulcers compared to a placebo. It included 54 adults and was stopped early, so the results …
Phase: PHASE3 • Sponsor: InflaRx GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental immune cell therapy for AML shows promise but trial halted early
Disease control TerminatedThis study tested a treatment called MT-401, which uses specially trained immune cells from a donor to fight acute myeloid leukemia (AML) after a stem cell transplant. The goal was to see if these cells could prevent or treat relapse. The trial enrolled 92 people but was stopped …
Phase: PHASE2 • Sponsor: Marker Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for blood cancer patients: drug shows promise in controlling disease
Disease control TerminatedThis study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug P1101 tested for rare bone marrow disease
Disease control TerminatedThis phase 2 trial tested a drug called P1101 (a type of interferon) in 11 people with early myelofibrosis, a rare bone marrow disorder. The goal was to see if the drug could shrink the spleen, improve symptoms, or boost blood counts. The study was terminated early, so the full r…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Myelofibrosis drug combo trial ends early – what it means
Disease control TerminatedThis phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink the spleen and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so the full results are not available. The goal was t…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug aims to stop leukemia relapse after transplant
Disease control TerminatedThis study tested a drug called sabatolimab, alone or with another drug, in 24 adults and teens with acute myeloid leukemia (AML) who had signs of leftover cancer after a stem cell transplant. The goal was to see if it could prevent the cancer from coming back without causing sev…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cell therapy targets tough childhood leukemia
Disease control TerminatedThis early-phase study tested a new treatment for children and young adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The treatment involved taking patients' own immune cells, engineering them to recognize and attack leukemia cells (CA…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New wound therapy for rare skin disease shows early promise
Disease control TerminatedThis study tested a treatment for pyoderma gangrenosum, a rare skin condition that causes painful, hard-to-heal ulcers. Researchers used a special wound covering made from donated placenta tissue (EpiFix) followed by skin grafts. The study was stopped early after only 5 people en…
Phase: PHASE4 • Sponsor: Louisiana State University Health Sciences Center in New Orleans • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental combo therapy for blood cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested two new drug combinations in 52 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). One group received HDM201 plus MBG453, the other HDM201 plus venetoclax. The main goal was to check safety and find the right dose. …
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental combo for tough blood cancers hits early snag
Disease control TerminatedThis early-stage trial tested a combination of two experimental drugs, VOB560 and MIK665, in 37 people with relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma. The drugs aim to block proteins that help cancer cells survive, forcing them to di…
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Knee implant study halted early: what we know
Disease control TerminatedThis study looked at how well the P.F.C. Sigma knee replacement implant works in people with severe knee arthritis. Researchers planned to follow 723 patients for at least 5 years after surgery, tracking pain, function, and any complications. However, the study was terminated ear…
Phase: PHASE4 • Sponsor: DePuy International • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a smartphone app replace doctor visits for arthritis patients?
Disease control TerminatedThis study tested whether using a smartphone app and a hand grip device could help people with rheumatoid arthritis manage their condition with fewer in-person doctor visits. About 94 adults with active rheumatoid arthritis were randomly assigned to use the app or continue standa…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control TerminatedThis study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…
Phase: PHASE2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for kids after transplant: study tests safer GVHD prevention
Disease control TerminatedThis study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to shrink spleen and ease symptoms in hard-to-treat myelofibrosis
Disease control TerminatedThis study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo for kids with resistant leukemia shows early promise but study halted
Disease control TerminatedThis study tested a targeted cancer drug called ponatinib combined with standard chemotherapy in children and young adults up to age 21 with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that had come back or stopped responding to other treatments. The g…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental leukemia drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose…
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug SGR-2921 tested for tough blood cancers – but trial halted early
Disease control TerminatedThis early-stage trial tested an experimental oral drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The main goals were to check safety and find the right dose. However, the study was terminated e…
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug namilumab tested for lung sarcoidosis – but trial halted early
Disease control TerminatedThis study tested namilumab, an experimental drug, in 107 people with chronic pulmonary sarcoidosis, a condition causing lung inflammation. The trial was randomized and placebo-controlled, but it was terminated early. The goal was to see if namilumab could reduce the need for res…
Phase: PHASE2 • Sponsor: Kinevant Sciences GmbH • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
Lupus drug combo tested in tiny trial – but study halted early
Disease control TerminatedThis phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 15:22 UTC
-
New drug combo for kids with tough leukemia shows promise but trial halted early
Disease control TerminatedThis trial tested the drug isatuximab, a targeted antibody, combined with standard chemotherapy in children aged 28 days to under 18 years whose acute leukemia had returned or stopped responding to treatment. The study aimed to see if the combination could help more children achi…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Experimental drug tested for Tough-to-Treat leukemia, but study stopped early
Disease control TerminatedThis phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…
Phase: PHASE2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 26, 2026 14:44 UTC
-
New PET tracer aims to reveal hidden immune activity in tumors and arteries
Diagnosis TerminatedThis Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…
Phase: PHASE2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis TerminatedThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase: PHASE1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention TerminatedThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Botox for groin pain? small study explores new treatment
Symptom relief TerminatedThis study tested whether injecting botulinum toxin A (Dysport) into the groin muscles could relieve chronic pain from adductor tendinopathy (pubalgia) in people who didn't get better with rest, anti-inflammatories, or physical therapy. Only 4 participants were enrolled before th…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Pain pill showdown: ultracet vs. voltaren for back inflammation
Symptom relief TerminatedThis study compared two pain medications—Ultracet (tramadol/acetaminophen) and Voltaren (diclofenac)—in people with ankylosing spondylitis who were already taking disease-modifying anti-rheumatic drugs (DMARDs). The goal was to see which one worked better for pain relief over 8 w…
Phase: PHASE4 • Sponsor: Johnson & Johnson Taiwan Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Pain patch put to the test for aching joints
Symptom relief TerminatedThis study tested a medicated patch containing ketoprofen (a pain reliever) for people with tendonitis or bursitis pain in the shoulder, elbow, or knee. About 381 adults with these conditions were randomly assigned to receive either the active patch or a placebo patch. The goal w…
Phase: PHASE3 • Sponsor: APR Applied Pharma Research s.a. • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Tennis elbow treatment study ends early: what we learned
Symptom relief TerminatedThis study looked at whether a special arm sleeve with embedded semiconductors, combined with injections of platelet-rich plasma and stem cells, could reduce pain and improve elbow function in people with tennis elbow. Only 5 adults aged 18-65 took part before the study was stopp…
Phase: NA • Sponsor: INCREDIWEAR HOLDINGS, INC. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Sarcoidosis drug study halted after only 2 patients enrolled
Symptom relief TerminatedThis study tested whether Acthar gel could improve symptoms and lung function in people with sarcoidosis, a disease that causes inflammation in the lungs. Researchers also checked if a blood marker called CXCL9 could predict how well the treatment works. Only 2 people joined befo…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 12:27 UTC
-
Can less pressure mean better fibroid surgery?
Symptom relief TerminatedThis study looked at whether using a lower fluid pressure (60 mmHg) during hysteroscopy, a procedure to remove fibroids, works as well as the standard pressure (80 mmHg). The goal was to see if it improves surgery time, fluid use, and surgeon's view. The study was stopped early a…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
New injection targets psoriatic arthritis pain in small trial
Symptom relief TerminatedThis early-stage study tested the safety of an experimental drug called Allocetra, injected directly into the joint, for people with psoriatic arthritis. Only 5 participants were enrolled. The main goal was to check for side effects, with some initial data on pain relief. The stu…
Phase: PHASE1 • Sponsor: Enlivex Therapeutics Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Laser hope for scars and scleroderma fizzles in tiny trial
Symptom relief TerminatedThis study tested whether a special laser could improve scars and skin hardening from scleroderma. Only 6 people took part, and the study was stopped early. Researchers measured scar changes using a standard scale, but the small size and early termination mean we cannot draw firm…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New bundled care approach aims to ease chronic pelvic pain
Symptom relief TerminatedThis study looked at whether a combined treatment plan—including physical therapy, behavioral health therapy, and medical procedures—could reduce symptoms of chronic bladder pain. Researchers compared this bundled approach to usual care in 26 women with interstitial cystitis or b…
Phase: PHASE3 • Sponsor: Jocelyn Fitzgerald • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Shoulder pain drug trial halted early
Symptom relief TerminatedThis study tested whether the drug secukinumab could reduce pain and improve function in adults with moderate to severe rotator cuff tendinopathy, a common shoulder condition. Participants received either the drug or a placebo for 24 weeks. The trial was terminated early, and res…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Which radiotherapy plan best eases bone metastasis symptoms?
Symptom relief TerminatedThis study compared two ways of giving palliative radiotherapy to people with cancer that has spread to the bones. The goal was to see which method better controls nausea and vomiting caused by radiation, while also managing pain. About 160 adults with bone metastases took part, …
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New bladder pain cocktail tested – but study halted early
Symptom relief TerminatedThis study tested a single dose of URG101, a combination of lidocaine and heparin, to see if it safely reduces bladder pain in people with Interstitial Cystitis/Bladder Pain Syndrome. The trial was randomized and double-blind, meaning neither patients nor doctors knew who got the…
Phase: PHASE2 • Sponsor: Urigen • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Precision brain radiation aimed at easing cancer bone pain
Symptom relief TerminatedThis study tested whether a single, highly focused dose of radiation to a tiny part of the brain (the pituitary gland) could help relieve severe, hard-to-treat bone pain caused by cancer that has spread. Only 5 people took part, and the study was stopped early. The goal was to se…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
New drug aimed at shoulder pain fails to complete trial
Symptom relief TerminatedThis study tested the drug secukinumab against a placebo in 60 adults with moderate to severe rotator cuff tendinopathy, a painful shoulder condition. The goal was to see if secukinumab could improve symptoms and shoulder function over 24 weeks. However, the trial was terminated …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Could a tiny ear device ease arthritis pain in kids?
Symptom relief TerminatedThis study tested whether a small device that sends mild electrical pulses to the vagus nerve (through the ear) can reduce pain and inflammation in children with juvenile idiopathic arthritis. The trial planned to enroll children ages 5 to 18, but was terminated early after only …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Tiny study on blood flow cuffs for shoulder injuries ends early
Symptom relief TerminatedThis study tested whether using a blood flow restriction (BFR) cuff during physical therapy could help people with shoulder injuries regain strength and return to activity faster. Only 3 people took part before the study was stopped early. The approach uses a special tourniquet t…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Radioactive treatment for bone pain in advanced prostate cancer tested, but study stopped early
Symptom relief TerminatedThis study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
RA patients paired with buddies to boost Well-Being
Symptom relief TerminatedThis study tested a program where people with rheumatoid arthritis (RA) were paired with a trained peer supporter for up to 6 months. The goal was to see if sharing experiences and support could improve daily function, medication adherence, and symptoms like pain and fatigue. The…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Leukemia relapse study halted: could a blood test have predicted it?
Knowledge-focused TerminatedThis study aimed to see if a sensitive molecular test could predict relapse in adults with acute myeloid leukemia (AML) who had a stem cell transplant. Researchers planned to follow 303 patients in remission, comparing outcomes between those with and without detectable disease ma…
Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Painkiller showdown: which is safer for the heart?
Knowledge-focused TerminatedThis study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…
Phase: PHASE4 • Sponsor: Platelet and Thrombosis Research, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Study aims to predict drug failure in rare blood cancer
Knowledge-focused TerminatedThis study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first t…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Scientists hunt for clues to tell infection apart from inflammation in Kids' joints
Knowledge-focused TerminatedThis study looked for new markers in blood and joint fluid to help doctors tell the difference between septic arthritis (a joint infection) and juvenile idiopathic arthritis (an inflammatory condition) in children. Researchers planned to analyze samples from 100 children under 15…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Superhero training for food allergy safety falls short
Knowledge-focused TerminatedThis study aimed to help children aged 6-8 from low-income families learn how to avoid foods they are allergic to. The program used fun, hands-on activities to teach safety skills. The study was stopped early, so we don't have clear results on whether it worked.
Phase: NA • Sponsor: Kent State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New lung camera could replace needle biopsies
Knowledge-focused TerminatedThis study aimed to see if a tiny camera on a thin tube (bronchoscopy) could help doctors diagnose diffuse lung diseases without needing a surgical lung biopsy. The camera takes live microscopic images of the air sacs. The study was stopped early, but it involved 38 adults with c…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Microscope inside the lungs reveals hidden damage in two diseases
Knowledge-focused TerminatedThis study used a special microscope on the tip of a thin tube (bronchoscope) to look at the smallest blood vessels in the lungs of people with scleroderma or emphysema. The goal was to see how these vessels change in each disease. Only 9 patients were enrolled before the study w…
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut microbiome study in kids with autoimmune diseases ends early
Knowledge-focused TerminatedThis study aimed to compare the gut bacteria of children newly diagnosed with juvenile idiopathic arthritis, type 1 diabetes, or inflammatory bowel disease with those of their healthy siblings. Researchers wanted to see if differences in gut microbes and diet could explain why so…
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Leukemia drug pill tested against IV version – but study halted early
Knowledge-focused TerminatedThis very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Arthritis drugs and COVID: study probes immune response
Knowledge-focused TerminatedThis study looked at how immunosuppressive medications used for rheumatoid arthritis and spondyloarthritis affect the body's ability to fight COVID-19. Researchers measured viral load and immune responses in 150 patients and their infected family members. The goal was to understa…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused TerminatedThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Sleep apnea study probes fat inflammation – CPAP may help
Knowledge-focused TerminatedThis study aimed to see if using a CPAP machine (a device that helps breathing during sleep) reduces inflammation in fat tissue for people with sleep apnea, both obese and non-obese. Researchers planned to compare CPAP treatment to a placebo in 40 men. The study was stopped early…
Phase: NA • Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Lupus and COVID vaccines: immune response under the microscope
Knowledge-focused TerminatedThis study aimed to understand how the COVID-19 vaccine impacts the immune system in people with lupus, a chronic autoimmune disease. Researchers planned to enroll lupus patients to measure their immune response to the vaccine and see if lupus disease activity or treatments affec…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
New hip implant put to the test: will it stay put?
Knowledge-focused TerminatedThis study looked at a specific hip implant shell (the Pinnacle Acetabular Shell) used in total hip replacement. Researchers wanted to see how much the implant moved (migrated) over two years using a special X-ray technique called RSA. They also tracked how patients felt and func…
Phase: NA • Sponsor: DePuy Orthopaedics • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New survey aims to better measure life quality in pituitary tumor patients
Knowledge-focused TerminatedThis study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Elderly arthritis study reveals hidden health risks
Knowledge-focused TerminatedThis study aimed to understand how age influences serious health issues like infections, cancer, heart disease, and bone fractures in people with rheumatoid arthritis. Researchers compared patients over 65 with younger adults (18-50) who had the same disease. The study was stoppe…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gene hunt in leukemia: what IDH mutations mean for patients
Knowledge-focused TerminatedThis study aimed to find how often IDH1 and IDH2 gene mutations occur in adults with acute myeloid leukemia (AML) in China, and whether those mutations affect a patient's chance of relapse or survival. Researchers planned to analyze stored leukemia samples from over 1,000 patient…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Lab study explores how JAK inhibitors affect immune cells in arthritis
Knowledge-focused TerminatedThis study looked at how JAK-STAT inhibitors, a type of drug used for rheumatoid arthritis, affect certain immune cells called regulatory B cells. Researchers analyzed blood samples from 27 patients to see if these drugs could boost anti-inflammatory functions. The study was term…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists probe immune cells in arthritic joints for clues
Knowledge-focused TerminatedThis pilot study analyzed special immune cells called regulatory T cells (Tregs) in the joint fluid of 19 people with rheumatoid arthritis during a flare-up. Researchers compared these cells to Tregs in the blood to understand how they behave in inflamed joints. No treatment was …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Scientists gather leftover surgical tissue to unlock secrets of bone disease
Knowledge-focused TerminatedThis study collected bone, cartilage, skin, and fat tissue from 50 patients undergoing surgery at Children's National Medical Center. The goal was to grow cells from these tissues in the lab and analyze them to better understand bone and connective tissue diseases. The study was …
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Tiny study probes hidden cause of foot pain in arthritis
Knowledge-focused TerminatedThis study looked at whether a condition called intermetatarsal bursitis (inflammation between foot bones) causes pain in people with rheumatoid arthritis. Researchers used MRI and ultrasound to examine the feet of 3 participants and tested steroid injections. The study was termi…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Study on arthritis and diabetes link halted early
Knowledge-focused TerminatedThis study looked at whether people with both rheumatoid arthritis and type 2 diabetes have a harder time controlling their diabetes than those with osteoarthritis and diabetes. Researchers planned to follow 176 adults to see how quickly they needed new diabetes treatments. Howev…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:07 UTC
-
Pregnancy registry for elagolix users launched, then stopped early
Knowledge-focused TerminatedThis registry aimed to track pregnancy outcomes in women who were exposed to elagolix (brand names Orilissa and Oriahnn) for endometriosis or uterine fibroids. The study planned to enroll 584 pregnant women, half with elagolix exposure and half without, and follow them through pr…
Sponsor: AbbVie • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:55 UTC
-
COVID-19 vaccine response under scrutiny in autoimmune patients
Knowledge-focused TerminatedThis study looked at how well the COVID-19 vaccine triggers an immune response in people with autoimmune or inflammatory diseases who take immunosuppressants or biologics. Researchers took blood samples before vaccination and at several points after to measure antibodies and T-ce…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:24 UTC
-
Tiny study on drug monitoring in scleroderma ends early
Knowledge-focused TerminatedThis study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was termina…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:32 UTC